Anthony Tolcher, M.D.Director of Clinical Research, Founder and CEO at NEXT Oncology
Dr. Tolcher is CEO and Founder of NEXT OncologyTM, San Antonio, Texas, a newly founded Phase I group that seeks to transform early clinical trials. NEXT Oncology’s mission is to accelerate the next breakthrough medicines for cancer and the vision is to be the most successful and respected Phase I program in oncology research.
Dr. Tolcher served from 2009- 2018 as President and Co-Founder of START LLC, one of the world’s largest Clinical Phase I and early drug development operations in cancer medicine with 5 locations in San Antonio Texas; Grand Rapids, Michigan; Madrid Spain; Shanghai China; and Taipei, Taiwan
Dr. Tolcher is a medical oncologist who has over 25 years’ experience in early drug development and clinical trials. He has been involved in many of the initial phase I studies of new agents that subsequently were FDA approved for the treatment of cancer including pembrolizumab (KeytrudaÒ), copanlisib (Aliqopa), trastuzumab emtansine (KadcylaÒ), regorafenib (StivargaÒ), liposomal vincristine (MarqiboÒ), cabazitaxel (JevtanaÒ), carfilzomib (KyprolisÒ), gefitinib (IressaÒ), erlotinib (TarcevaÒ), and eribulin (HalavenÒ). He is currently the principal investigator on 20 phase I clinical studies, is a reviewer for the Journal of Clinical Oncology, Clinical Cancer Research, and Annals of Oncology. He has chaired the Developmental Therapeutics Review Committee for the American Association of Clinical Oncology Annual Scientific Program.
He has a member of over 20 Scientific Advisory Boards for both large and small pharmaceutical companies, as well as a member of the Board of Director for 2 biotechnology companies.
Dr. Tolcher has over 100 peer-reviewed publications in scientific journals including Nature, Proceedings of the National Academy of Sciences (USA), Journal of Clinical Oncology, and Clinical Cancer Research, as well as an author of nine book chapters.